Search alternatives:
marked decrease » marked increase (Expand Search)
small decrease » small increased (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
status small » stage small (Expand Search), status map (Expand Search)
marked decrease » marked increase (Expand Search)
small decrease » small increased (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
status small » stage small (Expand Search), status map (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20